Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.

Trial Details

NCT ID
NCT05797077
Phase
PHASE3
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Colorectal resection surgery.
  • FOLFOX chemotherapy regimen
  • Capecitabine
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Both males and females, aged 18-75 years;
  • Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have …
  • Postoperative ctDNA-positive patients;
  • ASA grade \< IV and/or ECOG performance status score ≤ 2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →